Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Aug 6, 2022; 10(22): 7708-7719
Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7708
Table 1 Baseline characteristics of the patients (n = 307)
Characteristics
Median (range) / n (%)
Age (yr)64 (44, 79)
Body mass index (kg/m2)22.2 (14.9, 31.6)
Disease course (months)2 (0.1, 36)
Sex (male)195 (63.5%)
Smoking95 (30.9%)
Drinking20 (6.5%)
Family history of esophagus cancer22 (7.2%)
Hypertension112 (36.5%)
Diabetes21 (6.8%)
Coronary heart disease16 (5.2%)
ASA stage
II233 (75.9%)
III73 (23.8%)
IV1 (0.3%)
Hemoglobin (g/L)141 (80, 180.4)
MCV (fl)93.6 (71.1, 134.1)
Platelets (× 109/L)213 (60.3, 445.9)
Lymphocytes (× 109/L)1.56 (0.07, 7.42)
Monocytes (× 109/L)0.36 (0.05, 1.01)
Neutrophils (× 109/L)3.63 (1.15, 12.94)
PT (s)13.8 (11.4, 31.9)
APTT (s)31.4 (10.6, 51.7)
Fibrinogen (g/L)3.79 (1.95, 6.3)
D-dimer (ng/mL)130 (14, 3354)
Total protein (g/L)71 (3.32, 88.1)
Albumin (g/L)42.1 (26.1, 63.5)
Creatinine (µmol/L)63 (36, 187)
Hematocrit (%)46.6 (28.2, 64.5)
Table 2 Treatment related information (n = 307)
Variables
Median (range) / n (%)
Tumor location
Upper15 (4.9%)
Middle to upper21 (6.8%)
Middle171 (55.7%)
Middle to lower43 (14.0%)
Lower57 (18.6%)
Tumor diameter (cm)3 (0, 10)
T stage
Tis30 (9.8%)
1a4 (1.3%)
1b69 (22.5%)
275 (24.4%)
391 (29.6%)
4a36 (11.7%)
4b2 (0.7%)
N stage
0215 (70.0%)
161 (19.9%)
228 (9.1%)
33 (1.0%)
G stage
030 (9.8%)
121 (6.8%)
1-273 (23.8%)
2148 (48.2%)
2-324 (7.8%)
311 (3.6%)
pTNM
030 (9.8%)
I108 (35.2%)
II71 (23.1%)
III87 (28.3%)
IVA11 (3.6%)
Pathological type
Squamous cell carcinoma268 (87.3%)
Intraepithelial neoplasia30 (9.8%)
Adenocarcinoma8 (2.6%)
Signet-ring cell carcinoma1 (0.3%)
Neoadjuvant radiotherapy and/or chemotherapy51 (16.6%)
Surgery
Mediastinoscopy/ laparoscopy/thoracoscopy258 (84.0%)
Thoracotomy/laparotomy27 (8.8%)
Endoscopic submucosal dissection22 (7.2%)
Resection
R0304 (99.0%)
R13 (1.0%)
Operation time (min)270 (36, 485)
Intraoperative blood loss (mL)150 (2, 1000)
Lymph node dissection283 (92.2%)
Postoperative treatment
None213 (69.4%)
Radiotherapy alone7 (2.3%)
Chemotherapy alone77 (25.1%)
Radiotherapy + chemotherapy10 (3.3%)
Number of metastatic lymph nodes0 (0, 8)
Table 3 Postoperative complications, recurrence, metastasis, and mortality (n = 307)
Variables
Median (range) / n (%)
Clavien-Dindo stage
None109 (35.5%)
I27 (8.8%)
II121 (39.4%)
IIIa28 (9.1%)
IIIb4 (1.3%)
IV4 (1.3%)
IVa8 (2.6%)
IVb6 (2.0%)
CCI, median (range)20.9 (0, 96.6)
Anastomotic leakage75 (24.4%)
Secondary operation7 (2.3%)
Hypoalbuminemia88 (28.7%)
Pulmonary infection68 (22.1%)
Recurrence11 (3.6%)
Metastasis21 (6.8%)
In-hospital mortality52 (16.9%)
30-day mortality61 (19.9%)
90-day mortality78 (25.4%)
Table 4 Univariable and multivariable Cox regression analyses of overall survival
Univariable
Multivariable
HR
95%CI
P
HR
95%CI
P
Age1.0180.979, 1.0590.377
Sex
Femaleref
Male1.0200.58, 1.7960.945
Body mass index
< 28ref
≥ 281.9120.816, 4.4780.136
Smoking1.1850.663, 2.1180.567
Drinking0.9160.285, 2.9420.882
Family history of esophagus cancer1.3720.545, 3.4520.501
Hypertension0.9390.530, 1.6630.829
Diabetes1.8980.810, 4.4490.140
Hemoglobin0.9870.971, 1.0040.125
D-dimer1.0000.999, 1.0010.782
Albumin1.0040.945, 1.0670.897
Creatinine1.0201.003, 1.0360.0201.0161, 1.0320.050
Tumor diameter1.2441.083, 1.4290.002
T stage
Tis/0-2refref
3-42.3271.331, 4.0680.0031.8690.98, 3.5640.058
N stage
0ref
1-32.8691.659, 4.962< 0.001
G stage
< 2ref
≥ 21.9901.062, 3.730.032
pTNM stage
0/I/IIrefref
III/IVA4.1172.349, 7.213< 0.0014.1892.190, 8.012< 0.001
Pathological type
Squamous cell carcinomaref
Others0.6160.222, 1.7110.353
Received preoperative radiotherapy or chemotherapy1.1570.592, 2.2610.669
Operation method
ESD/endoscopy/thoracoscopy/laparoscopyref
Thoracotomy/laparotomy0.8670.312, 2.4050.784
Lymph node dissection3.6220.500, 26.2550.203
Postoperative radiotherapy and/ or chemotherapy0.4490.225, 0.8970.0230.2340.112, 0.488< 0.001
Number of metastatic lymph nodes1.2771.109, 1.4710.001
CCI1.0291.014, 1.044< 0.0011.0181.004, 1.0320.011